Inflammation to cancer: The molecular biology in the pancreas (Review)
- Authors:
- Sunbin Ling
- Tingting Feng
- Kaiqi Ji
- Yu Tian
- Yan Li
-
Affiliations: Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China, Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China, Institute of Cancer Stem Cells, Dalian Medical University, Dalian, Liaoning 116044, P.R. China - Published online on: March 28, 2014 https://doi.org/10.3892/ol.2014.2003
- Pages: 1747-1754
This article is mentioned in:
Abstract
Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar | |
Batty GD, Kivimaki M, Morrison D, et al: Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall Study. Cancer Epidemiol Biomarkers Prev. 18:673–675. 2009. View Article : Google Scholar : PubMed/NCBI | |
Landi S: Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res. 681:299–307. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lowenfels AB and Maisonneuve P: Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 20:197–209. 2006. View Article : Google Scholar : PubMed/NCBI | |
Genkinger JM, Spiegelman D, Anderson KE, et al: Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 18:765–776. 2009. View Article : Google Scholar : PubMed/NCBI | |
Hassan MM, Bondy ML, Wolff RA, et al: Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 102:2696–2707. 2007. View Article : Google Scholar : PubMed/NCBI | |
Peek RM Jr and Crabtree JE: Helicobacter infection and gastric neoplasia. J Pathol. 208:233–248. 2006. View Article : Google Scholar : PubMed/NCBI | |
Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI | |
Canavan C, Abrams KR and Mayberry J: Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 23:1097–1104. 2006. | |
Solaymani-Dodaran M, Logan RF, West J, Card T and Coupland C: Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut. 53:1070–1074. 2004. | |
Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar | |
Ekbom A, McLaughlin JK, Karlsson BM, et al: Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst. 86:625–627. 1994. View Article : Google Scholar : PubMed/NCBI | |
Talamini G, Falconi M, Bassi C, et al: Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol. 94:1253–1260. 1999. View Article : Google Scholar : PubMed/NCBI | |
Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 328:1433–1437. 1993. View Article : Google Scholar : PubMed/NCBI | |
Maisonneuve P, Lowenfels AB, Müllhaupt B, et al: Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. Gut. 54:510–514. 2005. View Article : Google Scholar : PubMed/NCBI | |
Doll R, Peto R, Hall E, Wheatley K and Gray R: Mortality in relation to consumption of alcohol: 13 years’ observations on male British doctors. BMJ. 309:911–918. 1994. | |
Bracci PM, Wang F, Hassan MM, Gupta S, Li D and Holly EA: Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control. 20:1723–1731. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bansal P and Sonnenberg A: Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology. 109:247–251. 1995. View Article : Google Scholar : PubMed/NCBI | |
Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J and Whitcomb DC: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 89:442–446. 1997. View Article : Google Scholar : PubMed/NCBI | |
Chari ST, Mohan V, Pitchumoni CS, Viswanathan M, Madanagopalan N and Lowenfels AB: Risk of pancreatic carcinoma in tropical calcifying pancreatitis: an epidemiologic study. Pancreas. 9:62–66. 1994. View Article : Google Scholar : PubMed/NCBI | |
Ji B, Tsou L, Wang H, Gaiser S, et al: Ras activity levels control the development of pancreatic diseases. Gastroenterology. 137:1072–1082. 2009. View Article : Google Scholar : PubMed/NCBI | |
Wang Z, Ali S, Banerjee S, et al: Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol. 228:556–562. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bishop M, Xenoulis P and Steiner JM: Association between this SPINK1 variant and clinically detectable pancreatitis. J Vet Intern Med. 27:427–428. 2013.PubMed/NCBI | |
Hucl T, Jesnowski R, Pfützer RH, Elsässer HP and Löhr M: SPINK1 variants in young-onset pancreatic cancer. J Gastroenterol. 42:5992007. View Article : Google Scholar : PubMed/NCBI | |
Schlosser W, Schlosser S, Ramadani M, Gansauge F, Gansauge S and Beger HG: Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas. 25:26–30. 2002. View Article : Google Scholar : PubMed/NCBI | |
Vinokurova LV, Berezina OI, Drozdov VN, Petrakov AV and Nilova TV: Nitric oxide and indicators of oxidative stress in patients with exacerbation of chronic pancreatitis. Eksp Klin Gastroenterol. 2:75–81. 2011.(In Russian). | |
Bernards A and Settleman J: GAP control: regulating the regulators of small GTPases. Trends Cell Biol. 14:377–385. 2004. View Article : Google Scholar : PubMed/NCBI | |
Voice JK, Klemke RL, Le A and Jackson JH: Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem. 274:17164–17170. 1999. View Article : Google Scholar : PubMed/NCBI | |
Maekawa M, Nishida E and Tanoue T: Identification of the anti-proliferative protein Tob as a MAPK substrate. J Biol Chem. 277:37783–37787. 2002. View Article : Google Scholar : PubMed/NCBI | |
Roux PP, Ballif BA, Anjum R, Gygi SP and Blenis J: Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA. 101:13489–13494. 2004. View Article : Google Scholar : PubMed/NCBI | |
Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD and Downward J: Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 15:2442–2451. 1996.PubMed/NCBI | |
Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61:3986–3997. 2001.PubMed/NCBI | |
Rodriguez-Viciana P, Warne PH, Khwaja A, et al: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 89:457–467. 1997. View Article : Google Scholar : PubMed/NCBI | |
Mulligan NJ, Yang S, Andry C, Klein M and O’Brien MJ: The role of p21ras in pancreatic neoplasia and chronic pancreatitis. Hum Pathol. 30:602–610. 1999. View Article : Google Scholar : PubMed/NCBI | |
Mu DQ, Peng YS and Xu QJ: Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol. 10:471–475. 2004.PubMed/NCBI | |
Guerra C, Schuhmacher AJ, Cañamero M, et al: Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 11:291–302. 2007. View Article : Google Scholar | |
Logsdon CD and Ji B: Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. Clin Gastroenterol Hepatol. 7(11 Suppl): S40–S43. 2009. View Article : Google Scholar : PubMed/NCBI | |
Guerra C, Collado M, Navas C, et al: Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell. 19:728–739. 2011. View Article : Google Scholar : PubMed/NCBI | |
Collado M and Serrano M: Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 10:51–57. 2010. View Article : Google Scholar : PubMed/NCBI | |
Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C and Barbacid M: EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 22:318–330. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ardito CM, Grüner BM, Takeuchi KK, et al: EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell. 22:304–317. 2012. View Article : Google Scholar : PubMed/NCBI | |
Wang Z, Banerjee S, Ahmad A, et al: Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. PLoS One. 6:e205372011.PubMed/NCBI | |
Daniluk J, Liu Y, Deng D, et al: An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest. 122:1519–1528. 2012. | |
Friday BB and Adjei AA: K-ras as a target for cancer therapy. Biochim Biophys Acta. 1756:127–144. 2005.PubMed/NCBI | |
Kamisawa T, Takuma K, Tabata T, Egawa N and Yamaguchi T: Long-term follow-up of chronic pancreatitis patients with K-ras mutation in the pancreatic juice. Hepatogastroenterology. 58:174–176. 2011.PubMed/NCBI | |
Prescott SM and Fitzpatrick FA: Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 1470:M69–M78. 2000.PubMed/NCBI | |
Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI | |
Diaz A, Chepenik KP, Korn JH, Reginato AM and Jimenez SA: Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res. 241:222–229. 1998. View Article : Google Scholar : PubMed/NCBI | |
Aoki H, Ohnishi H, Hama K, et al: Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol. 292:C259–C268. 2007. View Article : Google Scholar : PubMed/NCBI | |
Koliopanos A, Friess H, Kleeff J, Roggo A, Zimmermann A and Büchler MW: Cyclooxygenase 2 expression in chronic pancreatitis: correlation with stage of the disease and diabetes mellitus. Digestion. 64:240–247. 2001. View Article : Google Scholar : PubMed/NCBI | |
O’Brien G, Shields CJ, Winter DC, Dillon JP, Kirwan WO and Redmond HP: Cyclooxygenase-2 plays a central role in the genesis of pancreatitis and associated lung injury. Hepatobiliary Pancreat Dis Int. 4:126–129. 2005.PubMed/NCBI | |
Albazaz R, Verbeke CS, Rahman SH and McMahon MJ: Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology. 5:361–369. 2005. View Article : Google Scholar : PubMed/NCBI | |
Niijima M, Yamaguchi T, Ishihara T, Hara T, Kato K, Kondo F and Saisho H: Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer. 94:1565–1573. 2002. View Article : Google Scholar : PubMed/NCBI | |
Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59:4356–4362. 1999.PubMed/NCBI | |
Kokawa A, Kondo H, Gotoda T, et al: Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 91:333–338. 2001. View Article : Google Scholar | |
Hillion J, Smail SS, Di Cello F, et al: The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology. 12:372–379. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kirane A, Toombs JE, Ostapoff K, et al: Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res. 18:5031–5042. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kong G, Kim EK, Kim WS, et al: Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol. 17:914–921. 2002. View Article : Google Scholar : PubMed/NCBI | |
Ding XZ, Tong WG and Adrian TE: Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20:2625–2631. 2000.PubMed/NCBI | |
Eibl G, Bruemmer D, Okada Y, et al: PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 306:887–897. 2003. View Article : Google Scholar : PubMed/NCBI | |
Colby JK, Klein RD, McArthur MJ, et al: Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia. 10:782–796. 2008.PubMed/NCBI | |
Furukawa F, Nishikawa A, Lee IS, et al: A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int J Cancer. 104:269–273. 2003. View Article : Google Scholar | |
Anderson KE, Johnson TW, Lazovich D and Folsom AR: Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst. 94:1168–1171. 2002. View Article : Google Scholar : PubMed/NCBI | |
Wenger FA, Kilian M, Achucarro P, et al: Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology. 2:54–60. 2002. View Article : Google Scholar : PubMed/NCBI | |
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar | |
Jacobs EJ, Connell CJ, Rodriguez C, et al: Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst. 96:524–528. 2004. View Article : Google Scholar : PubMed/NCBI | |
Schernhammer ES, Kang JH, Chan AT, et al: A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst. 96:22–28. 2004. View Article : Google Scholar : PubMed/NCBI | |
Yamamoto Y and Gaynor RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 107:135–142. 2001. View Article : Google Scholar : PubMed/NCBI | |
Shi Q, Le X, Abbruzzese JL, et al: Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res. 19:1363–1371. 1999. View Article : Google Scholar | |
Karin M, Cao Y, Greten FR and Li ZW: NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2:301–310. 2002. View Article : Google Scholar : PubMed/NCBI | |
Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI | |
Lu Z, Li Y, Takwi A, et al: miR-301a as an NF-κB activator in pancreatic cancer cells. EMBO J. 30:57–67. 2011. | |
Liptay S, Weber CK, Ludwig L, et al: Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer. 105:735–746. 2003. View Article : Google Scholar : PubMed/NCBI | |
Fujioka S, Sclabas GM, Schmidt C, et al: Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res. 9:346–354. 2003.PubMed/NCBI | |
Hoffmann A and Baltimore D: Circuitry of nuclear factor kappaB signaling. Immunol Rev. 210:171–186. 2006. View Article : Google Scholar : PubMed/NCBI | |
Qing G and Xiao G: Essential role of IkappaB kinase alpha in the constitutive processing of NF-kappaB2 p100. J Biol Chem. 280:9765–9768. 2005. View Article : Google Scholar : PubMed/NCBI | |
Carbone C and Melisi D: NF-κB as a target for pancreatic cancer therapy. Expert Opin Ther Targets. 16(Suppl 2): S1–S10. 2012. | |
Niu J, Li Z, Peng B and Chiao PJ: Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem. 279:16452–16462. 2004. View Article : Google Scholar | |
Melisi D, Niu J, Chang Z, et al: Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res. 7:624–633. 2009. View Article : Google Scholar | |
Barbie DA, Tamayo P, Boehm JS, et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462:108–112. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kazal LA, Spicer DS and Brahinsky RA: Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc. 70:3034–3040. 1948. View Article : Google Scholar | |
Witt H, Luck W, Hennies HC, et al: Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet. 25:213–216. 2000. View Article : Google Scholar : PubMed/NCBI | |
Schneider A, Barmada MM, Slivka A, Martin JA and Whitcomb DC: Clinical characterization of patients with idiopathic chronic pancreatitis and SPINK1 mutations. Scand J Gastroenterol. 39:903–904. 2004. View Article : Google Scholar : PubMed/NCBI | |
Chen JM, Mercier B, Audrezet MP, et al: Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic chronic pancreatitis. Gastroenterology. 120:1061–1064. 2001. View Article : Google Scholar : PubMed/NCBI | |
Pfützer RH, Barmada MM, Brunskill AP, et al: SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology. 119:615–623. 2000.PubMed/NCBI | |
Kuwata K, Hirota M, Nishimori I, Otsuki M and Ogawa M: Mutational analysis of the pancreatic secretory trypsin inhibitor gene in familial and juvenile pancreatitis in Japan. J Gastroenterol. 38:365–370. 2003. View Article : Google Scholar : PubMed/NCBI | |
Ohmuraya M, Hirota M, Araki M, et al: Autophagic cell death of pancreatic acinar cells in serine protease inhibitor Kazal type 3-deficient mice. Gastroenterology. 129:696–705. 2005. View Article : Google Scholar : PubMed/NCBI | |
Rebours V, Couvelard A, Sauvanet A, et al: Pancreatic intraepithelial neoplasia is associated with chronic pancreatitis due to serine protease inhibitor kazal type 1 and cystic fibrosis transmembrane conductance regulator mutations. Pancreas. 39:947–948. 2010. View Article : Google Scholar | |
Shimosegawa T, Kume K and Satoh K: Chronic pancreatitis and pancreatic cancer: prediction and mechanism. Clin Gastroenterol Hepatol. 7(11 Suppl): S23–S28. 2009. View Article : Google Scholar : PubMed/NCBI | |
Ogawa M, Matsuura N, Higashiyama K and Mori T: Expression of pancreatic secretory trypsin inhibitor in various cancer cells. Res Commun Chem Pathol Pharmacol. 55:137–140. 1987.PubMed/NCBI | |
Ozaki N, Ohmuraya M, Hirota M, et al: Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res. 7:1572–1581. 2009. View Article : Google Scholar | |
Ozaki N, Ohmuraya M, Ida S, et al: Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Sci. Mar 12–2013.(Epub ahead of print). | |
Oikawa T, Hitomi J, Kono A, et al: Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. Int J Pancreatol. 18:15–23. 1995.PubMed/NCBI | |
Korc M, Friess H, Yamanaka Y, et al: Chronic pancreatitis is associated with increased concentrations of epidermal growth factor receptor, transforming growth factor alpha, and phospholipase C gamma. Gut. 35:1468–1473. 1994. View Article : Google Scholar | |
Tonouchi A, Ohtsuka M, Ito H, et al: Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection. Am J Gastroenterol. 101:1601–1610. 2006. View Article : Google Scholar | |
Gouyer V, Fontaine D, Dumont P, et al: Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene. 27:4024–4033. 2008. View Article : Google Scholar | |
Lo YY and Cruz TF: Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol Chem. 270:11727–11730. 1995. View Article : Google Scholar : PubMed/NCBI | |
Liou GY and Storz P: Reactive oxygen species in cancer. Free Radic Res. 44:479–496. 2010. View Article : Google Scholar : PubMed/NCBI | |
Szatrowski TP and Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:794–798. 1991.PubMed/NCBI | |
Leung PS and Chan YC: Role of oxidative stress in pancreatic inflammation. Antioxid Redox Signal. 11:135–165. 2009. View Article : Google Scholar : PubMed/NCBI | |
Garcea G, Dennison AR, Steward WP and Berry DP: Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology. 5:514–529. 2005. View Article : Google Scholar : PubMed/NCBI | |
Lau AT, He QY and Chiu JF: A proteome analysis of the arsenite response in cultured lung cells: evidence for in vitro oxidative stress-induced apoptosis. Biochem J. 382:641–650. 2004. View Article : Google Scholar : PubMed/NCBI | |
Lau AT and Chiu JF: Proteomic and biochemical analyses of in vitro carcinogen-induced lung cell transformation: synergism between arsenic and benzo[a]pyrene. Proteomics. 6:1619–1630. 2006.PubMed/NCBI | |
Barchowsky A, Dudek EJ, Treadwell MD and Wetterhahn KE: Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med. 21:783–790. 1996. View Article : Google Scholar : PubMed/NCBI | |
Schoenberg MH, Birk D and Beger HG: Oxidative stress in acute and chronic pancreatitis. Am J Clin Nutr. 62(6 Suppl): 1306S–1314S. 1995.PubMed/NCBI | |
Kadlubar FF, Anderson KE, Häussermann S, et al: Comparison of DNA adduct levels associated with oxidative stress in human pancreas. Mutat Res. 405:125–133. 1998. View Article : Google Scholar : PubMed/NCBI | |
Cullen JJ, Mitros FA and Oberley LW: Expression of antioxidant enzymes in diseases of the human pancreas: another link between chronic pancreatitis and pancreatic cancer. Pancreas. 26:23–27. 2003. View Article : Google Scholar : PubMed/NCBI | |
Teoh ML, Sun W, Smith BJ, Oberley LW and Cullen JJ: Modulation of reactive oxygen species in pancreatic cancer. Clin Cancer Res. 13:7441–7450. 2007. View Article : Google Scholar : PubMed/NCBI | |
Benhar M, Engelberg D and Levitzki A: ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 3:420–425. 2002. View Article : Google Scholar : PubMed/NCBI | |
Martindale JL and Holbrook NJ: Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol. 192:1–15. 2002. View Article : Google Scholar : PubMed/NCBI | |
Leonard SS, Harris GK and Shi X: Metal-induced oxidative stress and signal transduction. Free Radic Biol Med. 37:1921–1942. 2004. View Article : Google Scholar : PubMed/NCBI | |
Shimojo Y, Akimoto M, Hisanaga T, et al: Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin Exp Metastasis. 30:143–154. 2013. View Article : Google Scholar | |
DeNicola GM, Karreth FA, Humpton TJ, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475:106–109. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hossain MZ and Kleve MG: Nickel nanowires induced and reactive oxygen species mediated apoptosis in human pancreatic adenocarcinoma cells. Int J Nanomedicine. 6:1475–1485. 2011. View Article : Google Scholar | |
Lau ST, Lin ZX and Leung PS: Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. Br J Cancer. 102:583–593. 2010. View Article : Google Scholar | |
Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Inves. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI | |
Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar | |
Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ and Ross JA: Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol. 21:881–886. 2002. | |
Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al: Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci. 54:683–689. 2009. View Article : Google Scholar : PubMed/NCBI | |
Miron N, Miron MM, Milea VG and Cristea V: Proinflammatory cytokines: an insight into pancreatic oncogenesis. Roum Arch Microbiol Immunol. 69:183–189. 2010.PubMed/NCBI | |
Dima SO, Tanase C, Albulescu R, et al: An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas. 41:1001–1007. 2012. View Article : Google Scholar : PubMed/NCBI | |
Matsuo Y, Takeyama H and Guha S: Cytokine network: new targeted therapy for pancreatic cancer. Curr Pharm Des. 18:2416–2419. 2012. View Article : Google Scholar : PubMed/NCBI | |
Maker AV, Katabi N, Qin LX, et al: Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 17:1502–1508. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wang CY, Mayo MW and Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 274:784–787. 1996. View Article : Google Scholar : PubMed/NCBI | |
Beg AA and Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:782–784. 1996. View Article : Google Scholar : PubMed/NCBI | |
McDade TP, Perugini RA, Vittimberga FJ Jr, Carrigan RC and Callery MP: Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells. J Surg Res. 83:56–61. 1999. View Article : Google Scholar : PubMed/NCBI | |
Baran B, Bechyne I, Siedlar M, et al: Blood monocytes stimulate migration of human pancreatic carcinoma cells in vitro: the role of tumour necrosis factor - alpha. Eur J Cell Biol. 88:743–752. 2009. View Article : Google Scholar | |
Feurino LW, Zhang Y, Bharadwaj U, et al: IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther. 6:1096–1100. 2007. View Article : Google Scholar : PubMed/NCBI | |
Block KM, Hanke NT, Maine EA and Baker AF: IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas. 41:773–781. 2012.PubMed/NCBI | |
Ebrahimi B, Tucker SL, Li D, Abbruzzese JL and Kurzrock R: Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 101:2727–2736. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kamohara H, Takahashi M, Ishiko T, Ogawa M and Baba H: Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol. 31:627–632. 2007. | |
Hussain F, Wang J, Ahmed R, et al: The expression of IL-8 and IL-8 receptors in pancreatic adenocarcinomas and pancreatic neuroendocrine tumours. Cytokine. 49:134–140. 2010. View Article : Google Scholar : PubMed/NCBI | |
Le X, Shi Q, Wang B, et al: Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res. 20:935–946. 2000. View Article : Google Scholar : PubMed/NCBI | |
Xu X, Wang Y, Chen J, et al: High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg. 16:1493–1498. 2012. View Article : Google Scholar : PubMed/NCBI | |
Grote VA, Kaaks R, Nieters A, et al: Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer. 106:1866–1874. 2012.PubMed/NCBI | |
Schmieder A, Multhoff G and Radons J: Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 60:514–521. 2012. View Article : Google Scholar | |
Bonifazi M, Gallus S, Bosetti C, et al: Aspirin use and pancreatic cancer risk. Eur J Cancer Prev. 19:352–354. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bradley MC, Hughes CM, Cantwell MM, et al: Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer. 102:1415–1421. 2010. View Article : Google Scholar : PubMed/NCBI | |
Rothwell PM, Fowkes FG, Belch JF, et al: Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI |